Porous starch: A novel carrier for solubility enhancement of carbamazepine

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 919-926

  Ali, Meer Tarique ^a   Fule, Ritesh ^a   Sav, Ajay ^a   Amin, Purnima ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

carbamazepine; dissolution; solubility enhancement

Indexed keywords

CARBAMAZEPINE; DRUG CARRIER; GENERIC DRUG; POROUS STARCH; SOLVENT; STARCH; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION;

ANTICONVULSANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAMAZEPINE; KINETICS; MICROSCOPY, ELECTRON, SCANNING; POWDER DIFFRACTION; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84890245470     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9985-6     Document Type: Article

References (35)

1. Hussain A, Rytting JH. Prodrug approach to enhancement of rate of dissolution of allopurinol. J Pharm Sci. 1974;63(5):798-9.
2. Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GG, Taylor LS. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci. 2011;100(8):3316-31.
3. Jadhav GS, Vavia PR. Physicochemical in silico and in-vivo evaluation of danazole-β cyclodextrin complex. Int J Pharm. 2008;2008(352):5-16.
4. Ambrogi V, Perioli L, Pagano C, Marmottini F, Ricci M, Sagnella A, et al. Use of SBA-15 for furosemide oral delivery enhancement. Eur J Pharm Sci. 2012;46(1-2):43-8.
5. Tatavarti AS, Hoag SW. Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices. J Pharm Sci. 2006;95(7):1459-68.
6. Murdande SB, Pikal MJ, Shanker RM, Bogner RH. Solubility advantage of amorphous pharmaceuticals: II. Application of quantitative thermodynamic relationships for prediction of solubility enhancement in structurally diverse insoluble pharmaceuticals. Pharm Res. 2010;27(12):2704-14.
7. Meer TS, Sawant KP, Amin PD. Liquid anti solvent precipitation process for solubility modulation of bicalutamide. Acta Pharma. 2011;61(4):435-45.
8. Moffat AC, Osselton MD, Widdop Clarke B. Analysis of drugs and poisons, vol. II. London: Pharmaceutical Press; 2004. p. 747-49.
9. Ambrogi V, Perioli L, Marmottini F, Accorsi O, Pagano C, Ricci M, et al. Role of mesoporous silicates on carbamazepine dissolution rate enhancement. Microporous Mesoporous Mater. 2008;113(1-3):445-52.
10. Achumecher GE. Therapeutic drug monitoring. New York: Appleton and Lange; 1995. p. 345-95.
11. Tayel SA, Soliman II, Louis D. Improvement of dissolution properties of carbamazepine through application of liquisolid tablet technique. Eur J Pharm Biopharm. 2008;69(1):342-7.
12. Wang Z, Chen B, Quan G, Li F, Wu Q, Dian L, et al. Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica. Int J Nanomedicine. 2012;7(1):5807-18.
13. Wang M, Rutledge GC, Myerson AS, Trout BL. Production and characterization of carbamazepine nanocrystals by electrospraying for continuous pharmaceutical manufacturing. J Pharm Sci. 2012;101(3):1178-88.
14. Xu L, Ming L, Zhefei G, Lin H, Xin F, Chuanbin W. Improving the chemical stability of amorphous solid dispersion with cocrystal technique by hot melt extrusion. Pharm Res. 2012;29(3):806-17.
15. Rowe RC, Shesky PJ, Quinn ME. Handbook of pharmaceutical excipients. 6th ed. London: Pharmaceutical Press; 2009. p. 685-90.
16. Uthumporn U, Zaidul ISM, Karim AA. Hydrolysis of granular starch at sub-gelatinization temperature using a mixture of amylolytic enzymes. Food Bioprod Process. 2010;88(1):47-54.
17. Guan JJ, Hanna MA. Extruding foams from corn starch acetate and native corn starch. Biomacromolecules. 2004;5(6):2329-39.
18. Torres FG, Boccaccini AR, Troncoso OP. Microwave processing of starch based porous structures for tissue engineering scaffolds. J Appl Polym Sci. 2007;103(2):1332-9.
19. Manoi K, Rizvi SSH. Physicochemical characteristics of phosphorylated cross-linked starch produced by reactive supercritical fluid extrusion. Carbohydr Polym. 2010;81(3):687-94.
20. Wu C, Wang Z, Zhi Z, Jiang T, Zhang J, Wang S. Development of biodegradable porous starch foam for improving oral delivery of poorly water soluble drugs. Int J Pharm. 2011;403(1-2):162-9.
21. The United States Pharmacopeia (USP29). 29th ed. Rockville, MD: United States Pharmacopeial Convention Inc.; 2006.
22. Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm. 2007;65(1):26-38.
23. Korsemeyer RW, Gurney R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
24. Grzesiak AL, Lang M, Kim K, Matzger AJ. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci. 2003;92(11):2260-71.
25. Zhang B, Cui D, Liu M, Gong H, Huang Y, Han F. Corn porous starch: preparation, characterization and adsorption property. Int J Biol Macromol. 2012;50(1):250-6.
26. Vasko PD, Blackwell J, KoenigInfrared JL. Raman spectroscopy of carbohydrates: part II: normal coordinate analysis of α-D-glucose. Carbohydr Res. 1972;23(3):407-16.
27. Cael SJ, Koenig JL, Blackwell J. Infrared and Raman spectroscopy of carbohydrates: part III: Raman spectra of the polymorphic forms of amylose. Carbohydr Res. 1973;29(1):123-34.
28. Dinunzio JC, Miller DA, Yang W, Mcginity GW, Williams RO. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. Mol Pharm. 2008;5(6):968-80.
29. Chan L, Caixia L, Yuan L, Jian-Feng C. Formation of bicalutamide nanodispersion for dissolution rate enhancement. Int J Pharm. 2011;404(1-2):257-63.
30. Corrigan OI, Holohan EM. Amorphous spray-dried hydroflumethiazide- polyvinylpyrrolidone systems: physicochemical properties. J Pharm Pharmacol. 1984;36(4):217-21.
31. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoamines as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther. 2005;314(2):725-31.
32. Hoogerkamp A, Vis PW, Danhof M, Voskuyl RA. Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat. J Pharmacol Exp Ther. 1994;269(2):521-8.
33. Paschoa OED, Mandema JW, Voskuyl RA, Danhof M. Pharmacokinetic- pharmacodynamic modeling of the anticonvulsant and electroencephalogram effects of phenytoin in rats. J Pharmacol Exp Ther. 1998;284(2):460-6.
34. Qian D, Chang PR, Ma X. Preparation of controllable porous starch with different starch concentrations by the single or dual freezing process. Carbohydr Polym. 2011;86(3):1181-6.
35. Qian D, Anderson DP, Ma X. Preparation and properties of the succinic ester of porous starch. Carbohydr Polym. 2012;88(2):604-8.